GASTRIC CANCER THERAPEUTICS MARKET ANALYSIS

Gastric Cancer Therapeutics MarketSize and Trends

Gastric cancer, also known as stomach cancer, is a type of cancer that develops within the inside layer of the stomach. Symptoms may include upper abdominal pain, yellowing of the skin, heartburn, sudden weight loss, blood in the stool, loss of appetite, and nausea, among others. This type of cancer may multiply to unaffected parts of the body mainly to the lungs, liver, the lining of the abdomen, lymph nodes, and bones. The key cause of gastric cancer is contagion by Helicobacter pylori. This accounts for around 60% of the gastric cancer cases. Some types of H. pylori comprise larger risks than the others. Some of the other causes include smoking and eating pickled vegetables. Around 1 in 10 cases of gastric cancer are inherited and 1% to 3% of the cases are due to hereditary syndromes such as hereditary gastric cancer. Most cases of gastric cancers are gastric carcinomas.

According to World Cancer Research Fund International, 952,000 new cases of gastric cancer were diagnosed in 2012. Gastric cancer was the fifth-most common type of cancer in the world. This epidemic has forced researchers, doctors, and governments to adopt various therapeutic treatments related to gastric cancer. An increase in investment by the companies and regulations by the government encouraging research on the same has provided significant momentum to the growth of the gastric cancer therapeutics market. This trend is likely to persist throughout the forecast period, since the number of cases of gastric cancer around the globe is rising at an alarming rate.

Gastric cancer therapeutics market taxonomy

On the basis of type of treatment, the global market is classified into:

• Surgery
• Targeted drugs therapy
• Chemotherapy
• Radiation therapy
• Others

On the basis of end user, the global market is classified into:

• Hospitals
• Clinics
• Specialized cancer treatment centers
• Ambulatory surgical centers
• Others

According to National Cancer Institute, there were a projected 79,843 individuals with stomach cancer in the U.S. alone, in 2013. According to the same report, gastric cancer represented a whopping 1.6% of the new cancer cases reported in the U.S. According to the National Cancer Institute, an estimated 26,370 new cases of the disease were reported, leading to 10,730 deaths in the U.S. in 2016. Rising incidence of stomach cancer in the U.S., positions it as a high growth market for gastric cancer therapeutics.

Increasing prevalence of the disease in the Asia to drive growth of overall gastric cancer therapeutics market

Survival rate for stomach cancer is greatly dependent upon the stage or phase of the disease during diagnosis. The earlier the stage of the disease progression, the higher is the survival rate. In Asia Pacific, the majority of the cases are detected at the later stage of the disease and predominantly among the geriatric population. Growth of the geriatric population in the region is leading to a proportional increase in occurrence of gastric cancer. This factor, along with growing health awareness leading to a rise in demand for early detection would fuel growth of the gastric cancer therapeutics industry over the forecast period.

Presently, the products available in the market constitutes of an extensive variety of treatment alternatives such as angiogenesis inhibitors, new chemotherapies and HER2-targeted therapy. However, demand for therapeutics that can take care of HER2-negative stomach cancer patients is high. Nevertheless, the gastric cancer market is experiencing a gradual change from generic treatment regimen to targeted therapies. This will further enhance the growth of the global gastric cancer therapeutics market.